Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference in Boston

QUÉBEC CITY, Aug. 2, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will make a corporate presentation at the upcoming Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 9, 2011, at 2 p.m. (Eastern Time) in the London Room of the Intercontinental Boston Hotel, in Boston.

A live webcast of the presentation will be available on Aeterna Zentaris' website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."